Quick Answer
CRISPR Therapeutics AG reported Total Revenue of $3.51 million for the year ending 2025.
- CRISPR Therapeutics AG showed a decrease of -90.6% in Total Revenue from 2024 to 2025.
- This data is from CRISPR Therapeutics AG's annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2015 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2015: $247.0 thousand | Q1 2016: $476.0 thousand | Q2 2016: $795.0 thousand | Q3 2016: $1.55 million | Q4 2016: $2.34 million | Q1 2017: $2.70 million | Q2 2017: $3.58 million | Q3 2017: $2.39 million | Q4 2017: $32.33 million | Q1 2018: $1.36 million | Q2 2018: $1.09 million | Q3 2018: $563.0 thousand | Q4 2018: $115.0 thousand | Q1 2019: $328.0 thousand | Q1 2019: $328.0 thousand | Q2 2019: $318.0 thousand | Q2 2019: $318.0 thousand | Q3 2019: $211.93 million | Q3 2019: $211.93 million | Q4 2019: $77.02 million | Q4 2019: $77.02 million | Q1 2020: $157.0 thousand | Q1 2020: $157.0 thousand | Q2 2020: $44.0 thousand | Q3 2020: $148.0 thousand | Q4 2020: $370.0 thousand | Q1 2021: $539.0 thousand | Q2 2021: $900.70 million | Q3 2021: $824.0 thousand | Q1 2022: $940.0 thousand | Q2 2022: $158.0 thousand | Q3 2022: $94.0 thousand | Q1 2023: $100.00 million | Q2 2023: $70.00 million | Q3 2023: $0.00 | Q1 2024: $504.0 thousand | Q2 2024: $517.0 thousand | Q3 2024: $602.0 thousand | Q1 2025: $865.0 thousand | Q2 2025: $892.0 thousand | Q3 2025: $889.0 thousand.
- Over the full 13 years of available data (2015 to 2025), CRISPR Therapeutics AG's Total Revenue has grown by 1,321.1%.
- Historical annual values: Fiscal year 2025: $3.51 million | Fiscal year 2024: $37.31 million | Fiscal year 2023: $371.21 million | Fiscal year 2022: $1.20 million | Fiscal year 2021: $914.96 million | Fiscal year 2020: $719.0 thousand | Fiscal year 2019: $289.59 million | Fiscal year 2019: $289.59 million | Fiscal year 2018: $3.12 million | Fiscal year 2018: $3.12 million | Fiscal year 2017: $41.00 million | Fiscal year 2016: $5.16 million | Fiscal year 2015: $247.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: